GlassScriptPhysician profile
Bryan Matthew Kaplan
NPI 1841911310
$881.96
in general payments reported to CMS, 2019-2025
13 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $382 · 2024: $372 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $483.16 | 2023-2025 | |
| Novo Nordisk INC | $92.79 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $72.17 | 2024-2025 | Eliquis |
| Glaxosmithkline, LLC. | $52.99 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $39.10 | 2024 | |
| Novartis Pharmaceuticals Corporation | $36.33 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $30.26 | 2024-2025 | Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $20.83 | 2024 | Rexulti |
| Scilex Pharmaceuticals INC. | $18.52 | 2023 | Ztlido |
| Alcresta Therapeutics, INC. | $14.00 | 2023 | Relizorb |
| Sumitomo Pharma America, INC. | $13.45 | 2024 | Gemtesa |
| Endogastric Solutions, INC | $7.19 | 2023 | Esophyx |
| Dynavax Technologies Corporation | $1.17 | 2024 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.